The multicenter, matched case-control study data collected for the acute brain bleeding analysis were used. 13 Patients who had experienced a HS, and who were aged 30 to 84 years and able to complete an interview, were recruited sequentially from 33 hospitals in Korea between 2002 and 2004. This study was approved by the Seoul National University Hospital/Seoul National University College of Medicine institutional review board, and all study participants provided written informed consent to participate.Background and Purpose-Research on the relationship between caffeine-containing medicines (CCMs) and the risk of hemorrhagic stroke (HS) is sparse. The aim of this study is to evaluate the association between CCMs and the risk of HS. Methods-We performed a multicenter case-control study in South Korea, from 2002 to 2004. A total of 940 patients with nontraumatic acute HS, aged 30 to 84 years without a history of stroke, 940 community, and 940 hospital controls, age and sex matched to each case, were included. We obtained information on all medications taken in the 14 days before the date (index date) and time of stroke onset (zero-time) for case subjects or matched zero-time for control subjects. Exposure to CCMs was defined by use on the index date before zero-time or during the preceding 3 days. The adjusted odds ratios and their 95% confidence intervals (CIs) were estimated by conditional logistic regression. Results-The adjusted odds ratio for the association between the use of CCM and risk for HS was 2.23 (95% CI, 1. 41-3.69) for all HS, 2.24 (95% CI, 1.08-4.66) for subarachnoid hemorrhage, and 2.49 (95% CI, 1.29-4.80) for intracerebral hemorrhage. Stratified by daily coffee intake, adjusted odds ratio of CCMs for HS was 2.95 (95% CI, 1.45-5.98) for those who did not drink coffee on a daily basis. Conclusions-These results suggest that use of CCMs is associated with increased risk of HS, both subarachnoid hemorrhage and intracerebral hemorrhage.
Identification of CasesWe screened all of the patients with HS admitted to the participating hospitals. HS was defined as either SAH or ICH. The diagnosis of SAH was based on clinical symptoms plus either a brain image (computed tomography [CT], MRI) or evidence of xanthochromia on a lumbar puncture. ICH was diagnosed on the basis of clinical symptoms and detection of blood in the brain parenchyma or ventricles by CT or MRI. Study eligibility criteria included ages ranging from 30 to 84 years, absence of a history of stroke or hemorrhage-prone brain lesions, no causal relationship of the stroke to trauma, and the ability to communicate and complete an interview within 30 days after the onset of the stroke. For each patient, we identified the zero-time as the calendar day (ie, index date) and the time of day that marked the onset of symptoms that were plausibly related to hemorrhage and that caused the patient to seek medical attention. 14 We defined the zero-time after considering the symptoms of hemorrhage, including paralysis, vertigo, disorders of memory, epile...